126 related articles for article (PubMed ID: 22712447)
1. The effect of instrumentation and laboratory site on the accuracy of the APTT-based heparin therapeutic range.
Marlar RA; Gausman JN
Int J Lab Hematol; 2012 Dec; 34(6):614-20. PubMed ID: 22712447
[TBL] [Abstract][Full Text] [Related]
2. The optimum number and types of plasma samples necessary for an accurate activated partial thromboplastin time-based heparin therapeutic range.
Marlar RA; Gausman J
Arch Pathol Lab Med; 2013 Jan; 137(1):77-82. PubMed ID: 23276178
[TBL] [Abstract][Full Text] [Related]
3. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
Marlar RA; Clement B; Gausman J
Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
[TBL] [Abstract][Full Text] [Related]
4. Inaccuracy of a "spiked curve" for monitoring unfractionated heparin therapy.
Gausman JN; Marlar RA
Am J Clin Pathol; 2011 Jun; 135(6):870-6. PubMed ID: 21571960
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of cumulative summation of differences method for determining APTT reagent suitability.
Findlater SH
Clin Lab Sci; 2012; 25(3):142-8. PubMed ID: 22953513
[TBL] [Abstract][Full Text] [Related]
6. Monitoring unfractionated heparin with the aPTT: time for a fresh look.
Eikelboom JW; Hirsh J
Thromb Haemost; 2006 Nov; 96(5):547-52. PubMed ID: 17080209
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of heparin-induced prolongation of APTT in 12 different laboratories in Kyushu area].
Tanaka N; Manabe M; Yamashita S; Ikeda K; Obayashi K; Uchiba M; Ando Y
Rinsho Byori; 2013 Jul; 61(7):576-82. PubMed ID: 24205697
[TBL] [Abstract][Full Text] [Related]
8. Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring.
Taylor CT; Petros WP; Ortel TL
Pharmacotherapy; 1999 Apr; 19(4):383-7. PubMed ID: 10212007
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a bedside device to assess the activated partial thromboplastin time for heparin monitoring in infants.
Klein RH; van der Vorst MM; de Wilde RB; Hogenbirk K; de Kam ML; Burggraaf J
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):327-31. PubMed ID: 23337708
[TBL] [Abstract][Full Text] [Related]
10. An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin.
Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Lloyd J; Street A; Marsden K;
Pathology; 2005 Jun; 37(3):234-8. PubMed ID: 16175898
[TBL] [Abstract][Full Text] [Related]
11. The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy.
Rosenberg AF; Zumberg M; Taylor L; LeClaire A; Harris N
J Pharm Pract; 2010 Jun; 23(3):210-6. PubMed ID: 21507816
[TBL] [Abstract][Full Text] [Related]
12. Monitoring unfractionated heparin with APTT: a French collaborative study comparing sensitivity to heparin of 15 APTT reagents.
Gouin-Thibaut I; Martin-Toutain I; Peynaud-Debayle E; Marion S; Napol P; Alhenc-Gelas M;
Thromb Res; 2012 May; 129(5):666-7. PubMed ID: 22169771
[No Abstract] [Full Text] [Related]
13. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.
Fritsma GA; Dembitzer FR; Randhawa A; Marques MB; Van Cott EM; Adcock-Funk D; Peerschke EI
Am J Clin Pathol; 2012 Jun; 137(6):904-8. PubMed ID: 22586049
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
Kitchen S; Preston FE
Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
[TBL] [Abstract][Full Text] [Related]
15. Use of the activated partial thromboplastin time for heparin monitoring.
Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
[TBL] [Abstract][Full Text] [Related]
16. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
17. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
Vandiver JW; Vondracek TG
Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
[TBL] [Abstract][Full Text] [Related]
18. Performance of Activated Partial Thromboplastin Time (APTT): Determining Reagent Sensitivity to Factor Deficiencies, Heparin, and Lupus Anticoagulants.
Kershaw G
Methods Mol Biol; 2017; 1646():75-83. PubMed ID: 28804819
[TBL] [Abstract][Full Text] [Related]
19. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
[TBL] [Abstract][Full Text] [Related]
20. [Correlation between aPTT and antifactor Xa to determine therapeutic ranges for unfractionated heparin].
Mariné L; Sánchez G; Vargas JF; Zúñiga P; Aizman A; Mertens R; Bergoeing M; Muñoz B
Rev Med Chil; 2014 Nov; 142(11):1392-7. PubMed ID: 25694284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
